Alphabet's Isomorphic Labs raises $5bn for AI drug design

Published · Updated · Based on reporting by The Next Web

Alphabet’s drug discovery unit Isomorphic Labs has secured $5bn in a Series C funding round. The investment was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and other investors participating. This announcement comes six months after the company raised $2.1bn in May. The capital will support the development of artificial intelligence models for pharmaceutical research.

Background

This latest funding follows a $2.1bn round raised in May of this year.

Why it matters

The massive investment highlights growing confidence in AI's potential to revolutionise pharmaceutical research.

Read the full coverage

More on: AI · Computers & Chips · #IsomorphicLabs · #Alphabet · #SequoiaCapital · #DemisHassabis

This brief was written with AI from the headlines and excerpts published by the outlets above, and may contain errors. Follow the links for the original reporting.